Agilent Technologies (A) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Agilent Technologies (NYSE:A) from a hold rating to a buy rating in a report issued on Thursday morning.

Several other equities research analysts also recently issued reports on the stock. Deutsche Bank raised their price objective on shares of Agilent Technologies from $77.00 to $80.00 and gave the stock a buy rating in a research note on Wednesday, August 15th. Morgan Stanley raised their price objective on shares of Agilent Technologies from $83.00 to $84.00 and gave the stock an overweight rating in a research note on Wednesday, August 15th. Finally, Zacks Investment Research upgraded shares of Agilent Technologies from a hold rating to a buy rating and set a $74.00 price target on the stock in a research note on Tuesday, August 7th. Ten equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus price target of $75.67.

Shares of Agilent Technologies stock opened at $68.85 on Thursday. The firm has a market capitalization of $21.65 billion, a PE ratio of 29.17, a P/E/G ratio of 2.33 and a beta of 1.35. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.00 and a current ratio of 3.62. Agilent Technologies has a 1 year low of $60.42 and a 1 year high of $75.00.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, August 14th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.04. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.20 billion. Agilent Technologies had a net margin of 6.20% and a return on equity of 18.61%. Agilent Technologies’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter last year, the company posted $0.59 earnings per share. sell-side analysts anticipate that Agilent Technologies will post 2.71 earnings per share for the current year.

In other Agilent Technologies news, Director Paul N. Clark sold 2,876 shares of Agilent Technologies stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $68.60, for a total transaction of $197,293.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Heidi Fields sold 5,482 shares of Agilent Technologies stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $67.73, for a total transaction of $371,295.86. The disclosure for this sale can be found here.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Advisors Capital Management LLC lifted its holdings in shares of Agilent Technologies by 1.5% during the second quarter. Advisors Capital Management LLC now owns 51,891 shares of the medical research company’s stock valued at $3,209,000 after acquiring an additional 759 shares during the period. SRS Capital Advisors Inc. lifted its holdings in shares of Agilent Technologies by 75.9% during the second quarter. SRS Capital Advisors Inc. now owns 1,791 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 773 shares during the period. Brinker Capital Inc. lifted its holdings in shares of Agilent Technologies by 14.2% during the first quarter. Brinker Capital Inc. now owns 6,334 shares of the medical research company’s stock valued at $424,000 after acquiring an additional 788 shares during the period. Advisor Partners LLC lifted its holdings in shares of Agilent Technologies by 8.8% during the second quarter. Advisor Partners LLC now owns 9,932 shares of the medical research company’s stock valued at $614,000 after acquiring an additional 803 shares during the period. Finally, Bamco Inc. NY lifted its holdings in shares of Agilent Technologies by 2.9% during the first quarter. Bamco Inc. NY now owns 28,808 shares of the medical research company’s stock valued at $1,927,000 after acquiring an additional 808 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Further Reading: Stock Symbols and CUSIP Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply